PCSS-X is a free, six-session course that was created to give practitioners guidance on implementing medications for the treatment of opioid use disorder (OUD) into your practice. The first live Zoom session is Thursday April 8 at 3:00 pm ET.
PCSS-X is intended for an interprofessional audience, and participants are welcome to attend whichever sessions are most relevant to their current situation. Please go here for a summary of each session. Prescribers with frontline experience prescribing medications for OUD and developing clinic workflows will be available during each session to answer participants’ questions and discuss real-world cases.
SESSION 1 – EXPLORE, PART 1 – April 8 AT 3:00 PM ET
Presenter(s): TBA
Facilitator: Sherry Larkins, PhD, Director of International Programs and Research Sociologist, Integrated Substance Abuse Programs at the University of California, Los Angeles – Semel Institute for Neuroscience and Human Behavior
Cost: No fee
Target Audience: Physicians, nurse practitioners or other advanced practice nurses, PAs, psychologists, social workers, clinical administrators and healthcare teams.
Credit Designations Available: AMA PRA Category 1 Credit™, Nursing Contact Hours, AAPA Category 1 CME credit, SW CE credit, and Interprofessional Continuing Education (IPCE) credit.
Webinar Description: Have you considered prescribing Medications for Opioid Use Disorder (MOUD) to treat your patients with opioid use disorder (OUD)? Have you wondered what is required to prescribe buprenorphine or other pharmacotherapies? If you answered yes to either or both of these questions, this PCSS Exchange session could provide you with the critical information and steps in determining the readiness of your site and clinical leadership. Initiating MOUD into your setting requires that you understand how pharmacotherapies work, including buprenorphine and its various formulations. Programs must think through the business case for service expansion and strategize how to best engage key staff.
Educational Objectives: At the conclusion of Session 1, participants should be able to:
- Summarize the financial and clinical considerations of incorporating MOUD into their practice
- Identify the three FDA-approved medications to treat opioid use disorder and describe the specific formulations of buprenorphine
- Identify resources targeted to non-prescribing members of healthcare teams (e.g., counselors, social workers, clinic administrators, etc.) and resources for prescribers (PCSS and others) to guide implementation of MOUD
Go here for more CME information.
https://conta.cc/3t3escv
